In conclusion, we herein report a successful conjugation of a GRPR antagonist and an albumin-binding domain that retained GRPR-targeting in vivo and, due to binding to albumin, resulted in a high and stable tumor uptake over several days. The gene discussed is GRPR; the disease is neoplasm.